1. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1-11.
2. Fan Y, Zhang C, Jin S, Gao Z, Cao J, Wang A et al. Progress of immune checkpoint therapy in the clinic (Review). Oncol Rep [review]. 2019;41:3-14.
3. Vigneron N. Human tumor antigens and cancer immunotherapy. BioMed Res Int. 2015;2015:948501.
4. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539-73.
5. Chae YK, Anker JF, Oh MS, Bais P, Namburi S, Agte S et al. Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. Sci Rep. 2019;9:3235.
6. Nouri Rouzbahani F, Shirkhoda M, Memari F, Dana H, Mahmoodi Chalbatani G, Mahmoodzadeh H et al. Immunotherapy a New Hope for cancer treatment: a review. Pak J Biol Sci. 2018;21:135-50.
7. Yi M, Qin S, Zhao W, Yu S, Chu Q, Wu K. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol. 2018;7:28.
8. Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A et al. Sensitive multiplexed quantitative analysis of autoantibodies to cancer antigens with chemically S-Cationized full-length and water-soluble denatured proteins. Bioconjug Chem. 2015;26:2076-84.
9. Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L et al. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018;2018:4325874.
10. Hutchison S, Pritchard AL. Identifying neoantigens for use in immunotherapy. Mamm Genome. 2018;29:714-30.
11. Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2005;26:77-86.
12. Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029-35.
13. Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006;28:463-8.
14. Hoshino IN, Y, Takiguchi N, Gunji H, Ishige F, Iwatate Y et al. Prognostic impact of autoantibody induction and gene expression in patients with esophageal cancer, gastric cancer, and hepatocellular cancer. Ann Gastroenterological Surg. 2020.
15. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014;46:467-73.
16. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46:1097-102.
17. Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet. 2015;96:597-611.
18. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677-83.
19. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41-7.
20. Xu YW, Peng YH, Chen B, Wu ZY, Wu JY, Shen JH et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2014;109:36-45.
21. Matejcic M, Gunter MJ, Ferrari P. Alcohol metabolism and oesophageal cancer: a systematic review of the evidence. Carcinogenesis. 2017;38:859-72.
22. Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut Pathog. 2016;8:8.
23. Hoshino I, Nagata M, Takiguchi N, Nabeya Y, Ikeda A, Yokoi S et al. Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci. 2017;108:308-15.
24. Shimada H, Fau KA, Shiratori T, Fau ST, Nomura F, Nomura F et al. Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer. (0944-1174 (Print)). J Gastroenterol. 2009;44:691-6.
25. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003;12:136-43.
26. Ushigome M, Nabeya Y, Soda H, Takiguchi N, Kuwajima A, Tagawa M et al. Multi-panel assay of serum autoantibodies in colorectal cancer. Int J Clin Oncol. 2018;23:917-23.
27. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649-58.
28. Suzuki T, Yajima S, Ishioka N, Nanami T, Oshima Y, Washizawa N et al. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma. Esophagus. 2018;15:294-300.
29. Shimada H. p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma. Ann Gastroenterological Surg. 2018;2:266-73.
30. Oshima Y, Shimada H, Yajima S, Nanami T, Matsushita K, Nomura F et al. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol. 2016;51:30-4.
31. Sato S, Noguchi Y, Wada H, Fujita S, Nakamura S, Tanaka R et al. Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. Int J Oncol. 2005;26:57-63.
32. Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M et al. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Clin Epigenet. 2018;10:79.
33. Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P et al. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10:237-46.
34. Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108:644-52.
35. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M et al. First-line nivolumab in Stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415-26.
36. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633-41.
37. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202-6.